Rona Therapeutics obtains global rights to Sanofi's siRNA platform
Category: #health  By Pankaj Singh  Date: 2022-07-25
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed targets.

These exclusive rights will allow Rona to substantially expand and expedite its siRNA portfolio in non-liver and liver applications.

The tech platform is an ideal fit for the Shanghai-based company in setting up industry-leading modification of oligonucleotides as well as expertise in RNA biology across a rapidly thriving pipeline.

Additionally, Sanofi obtains an exclusive alternative for selected muscular and neuro candidates found using the siRNA platform for regions outside Hong Kong, mainland China, Macao, and Taiwan.

Under the agreement, Rona also obtained rights to further manufacture, develop, and promote contenders from four preclinical programs targeting the liver.

Based on advanced conjugation moiety and nucleotide analogs, the siRNA platform has showcased improved stability and in vivo action time as well as the possibility for therapeutic silencing of target genes across various types of tissues.

Rona Therapeutics CEO, Stella Shi, stated that the company intends to advance program development in neurological, metabolic, and ocular diseases to tap into the capability of siRNA therapeutics.

As per the agreement, Rona will pay upfront to Sanofi in addition to commercial and development milestones along with royalties on net product sales. For the record, Rona Therapeutics is committed to discovering and developing programmable and modular RNA medicines to deliver to patients worldwide.

The company is established by industry veterans with extensive experience in the execution of RNA therapeutics programs and top scientific advisors with a deeper understanding of RNA biology.

Recently, Rona Therapeutics secured a Series A financing of USD 33 million to advance the initial pipeline of therapeutics and proprietary delivery platform. The round was backed by blue-chip investors including CMB International, Lilly Asia Ventures, Fontus Capital, Platanus, and Lanting Capital.

Source credit:

https://www.prnewswire.com/news-releases/rona-therapeutics-announces-exclusive-licensing-transaction-from-sanofi-for-its-broad-sirna-therapeutic-portfolio-and-technology-platform-301591673.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Zopper secures $75 million to address India’s insurance challenges

Zopper secures $75 million to address India’s insurance challenges

By Pankaj Singh

Renowned insurtech startup Zopper, has announced that it has secured $75 million in fresh funding, according to credible reports.

Over the course of more than five years, Zopper d...

LBS Smart Technology & Thinxtra to offer IoT-based hygiene solutions

LBS Smart Technology & Thinxtra to offer IoT-based hygiene solutions

By Pankaj Singh

Thinxtra, an Internet of Things (IoT) company, and LBS Smart Technology, a Hong Kong-based hygiene service-oriented technology company, have recently entered into a strategic collaboration to provide innovative hygiene...

Social media platforms make changes prior to US midterm elections

Social media platforms make changes prior to US midterm elections

By Pankaj Singh

Social media giants like Facebook and Twitter are reportedly announcing plans to protect the US midterm elections. The companies are generally staying the course from the 2020 voting session, which was battered by cons...